BioCryst Pharmaceuticals Inc (BCRX.OQ)
5.59USD
22 Jun 2018
$-0.18 (-3.12%)
$5.77
$5.77
$5.77
$5.35
623,221
233,962
$6.67
$3.95
About
Overall
| Beta: | 3.23 |
| Market Cap(Mil.): | $420.84 |
| Shares Outstanding(Mil.): | 80.47 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26
* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S
BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza
* BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA Source text for Eikon: Further company coverage:
BRIEF-Biocryst Pharmaceuticals And Idera Pharmaceuticals Reschedule Meetings To Vote On Proposed Merger
April 10 Idera Pharmaceuticals Inc - New Clinical Data On Idera's Imo :
BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst
* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS
BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals
* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS
BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals
* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS
BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema
* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA
BRIEF-Biocryst Reports Q4 Loss Per Share of $0.20
* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma
* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.
BRIEF-Great Point Reports 7.60 Pct Stake In BioCryst Pharmaceuticals
* GREAT POINT PARTNERS, LLC REPORTS 7.60 PERCENT STAKE IN BIOCRYST PHARMACEUTICALS INC AS OF FEBRUARY 6, 2018 - SEC FILING Source text: (http://bit.ly/2HjJO7H) Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| DAIICHI SANKYO COMPANY, LIMITED (4568.T) | ¥4,315 | -36.00 |
| Eisai Co., Ltd (4523.T) | ¥7,995 | -85.00 |
| Roche Holding Ltd. (ROG.S) | CHF216.45 | -- |
| Roche Holding Ltd. (RO.S) | CHF223.60 | +4.00 |
| GlaxoSmithKline plc (GSK.L) | 1,546.00 | +7.60 |
| Shire PLC (SHP.L) | 4,066.00 | -22.00 |
| Shire PLC (3159084.L) | -- | -- |
Estimates